Related references
Note: Only part of the references are listed.Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs
Yue Fei et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
C. Tsioufis et al.
CURRENT VASCULAR PHARMACOLOGY (2017)
Updates on cardiovascular outcome trials in diabetes
Oliver Schnell et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)
Guntram Schernthaner et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
Marit de Jong et al.
CARDIOVASCULAR DIABETOLOGY (2017)
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction
Mei-Tzu Wang et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
Zeqing Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
James Xu et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus
Huilin Tang et al.
AMERICAN JOURNAL OF CARDIOLOGY (2016)
Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis
Byron J. Hoogwerf et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
Keith C. Ferdinand et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
Christian Sonesson et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications A Worthwhile Effort?
Philippe Gabriel Steg et al.
CIRCULATION (2016)
Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes
Karen S. L. Lam et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Robert J. Smith et al.
DIABETES CARE (2016)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2016 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2016)
Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis
Gianluigi Savarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes A Meta-analysis
Suetonia C. Palmer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
Jason H. Y. Wu et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Miles Fisher et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On!
Saul Genuth
DIABETES CARE (2015)
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Elizabeth R. Seaquist et al.
DIABETES CARE (2013)
Evaluation of inconsistency in networks of interventions
Areti Angeliki Veroniki et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2013)
Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
Craig J. Currie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study
Christianne L. Roumie et al.
ANNALS OF INTERNAL MEDICINE (2012)
Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression
Ian R. White et al.
RESEARCH SYNTHESIS METHODS (2012)
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Wendy L. Bennett et al.
ANNALS OF INTERNAL MEDICINE (2011)
Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry
Diethelm Tschoepe et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Georgia Salanti et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
Ajay D. Rao et al.
DIABETES CARE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone
Alexander Cobitz et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus
Shari Bolen et al.
ANNALS OF INTERNAL MEDICINE (2007)
Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up
EZ Fisman et al.
CLINICAL CARDIOLOGY (2001)